NEWS HOURS

NEWS LOGIN

NEWS IPC8

Welcome to STN International! Enter x:X LOGINID: SSPTACDR1614 PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 * * * * * * * * * * Welcome to STN International Web Page for STN Seminar Schedule - N. America NEWS NEWS JAN 02 STN pricing information for 2008 now available NEWS JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats NEWS 5 JAN 28 MARPAT searching enhanced NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements NEWS 9 FEB 08 STN Express, Version 8.3, now available NEWS 10 FEB 20 PCI now available as a replacement to DPCI NEWS 11 FEB 25 IFIREF reloaded with enhancements NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification IFICDB, IFIPAT, and IFIUDB enhanced with new custom NEWS 14 MAR 31 IPC display formats NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued WPIDS, WPINDEX, and WPIX enhanced with new NEWS 20 APR 15 predefined hit display formats EMBASE Controlled Term thesaurus enhanced NEWS 21 APR 28 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,

Enter NEWS followed by the item number or name to see news on that specific topic.

Welcome Banner and News Items

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

For general information regarding STN implementation of IPC 8

STN Operating Hours Plus Help Desk Availability

FILE 'HOME' ENTERED AT 18:03:44 ON 21 MAY 2008

=> file reg
COST IN U.S. DOLLARS

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
0.21
0.21

FILE 'REGISTRY' ENTERED AT 18:03:54 ON 21 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8 DICTIONARY FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting ${\tt SmartSELECT}$ searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Queries\10566094.str

chain nodes :

10 11 12 13 14 15 16 23

ring nodes :

1 2 3 4 5 6 7 8 9 17 18 19 20 21 22

chain bonds :

2-15 7-10 10-11 11-12 12-13 12-14 15-16 16-22 21-23

ring bonds :

exact/norm bonds :

2-15 5-7 6-9 7-8 8-9 15-16 16-22 21-23

exact bonds :

7-10 10-11 11-12 12-13 12-14

normalized bonds :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS

L1 STRUCTURE UPLOADED

=> s 11 sss sam

SAMPLE SEARCH INITIATED 18:04:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 200 TO 800 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 18:04:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 576 TO ITERATE

100.0% PROCESSED 576 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 844831-94-3 REGISTRY

ED Entered STN: 10 Mar 2005

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-(CA INDEX NAME)

MF C18 H20 N4 O4 S

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus COST IN U.S. DOLLARS

ENTRY SESSION FULL ESTIMATED COST 180.82 181.03

FILE 'CAPLUS' ENTERED AT 18:05:11 ON 21 MAY 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 May 2008 VOL 148 ISS 21 FILE LAST UPDATED: 20 May 2008 (20080520/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 13

3 L3 L4

=> d ibib abs hitstr 1-3

ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136598 CAPLUS

DOCUMENT NUMBER: 142:240323

TITLE: Active substance combination comprising a compound

with NPY receptor affinity and a compound with 5-HT6

SINCE FILE

TOTAL

receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras,

> Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa,

Jordi; Buschmann, Helmut-Heinrich Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PATENT NO	KIND		DATE			APPLICATION NO.						DATE			
WO 2005014045			A1	20050217			,	WO 2	004-	20040729					
W: A	ΑE, AG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
C	CN, CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
G	SE, GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,
L	K, LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	ΝI,
N	IO, NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,

```
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
                                            ES 2003-1815
     ES 2228268
                          Α1
                                20050401
                                                                   20030730
     ES 2228268
                          В1
                                20060701
     AU 2004262488
                          Α1
                                20050217
                                            AU 2004-262488
                                                                   20040729
     CA 2534099
                          Α1
                                20050217
                                            CA 2004-2534099
                                                                   20040729
     EP 1660131
                                20060531
                                            EP 2004-741321
                                                                   20040729
                         Α1
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     MX 2006PA01230
                         Α
                                20060515
                                            MX 2006-PA1230
                                                                   20060130
     US 20070009597
                          Α1
                                20070111
                                            US 2006-566402
                                                                   20060705
PRIORITY APPLN. INFO.:
                                            ES 2003-1815
                                                                A 20030730
                                            WO 2004-EP8514
                                                                W 20040729
                       CASREACT 142:240323; MARPAT 142:240323
OTHER SOURCE(S):
GΙ
```

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.;
 - A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un) saturated (hetero) cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.). 844831-94-3P
 - RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

ΤT

- (preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and $5-\mathrm{HT}6$ receptor affinity) 844831-94-3 CAPLUS
- RN 844831-94-3 CAPLUS
 CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro(CA INDEX NAME)

REFERENCE COUNT: THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136568 CAPLUS

DOCUMENT NUMBER: 142:240322

TITLE: Active substance combination comprising a compound

with NPY receptor affinity and a compound with 5-HT6

receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras,

Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa,

Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 451 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA.	KIND DATE				APPL	ICAT:	ION I	DATE									
WO	0 2005014000			A1 20050217			WO 2004-EP8515					20040729					
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	${\sf TZ}$,	UG,	ZM,	ZW,	AM,
							RU,										
							GR,										
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	${ m ML}$,	MR,	NE,
		SN,	TD,	ΤG													
ES 2228267								ES 2003-1814					20030730				
ES	S 2228267																
AU 2004262489											20040729						
CA 2534100								CA 2	004 - 1	2534:	20040729						
EP	EP 1648468							EP 2	004 -	7636:	20040729						
	R:		•		•		ES,					•	•	•		MC,	PT,
							RO,										
MX 2006PA01232			А	20060515				MX 2006-PA1232									
US	US 20070059364				A1 20070315				US 2006-566100								
ORITY APPLN. INFO.:													A 20030730				
						WO 2004-EP8515					W 20040729						
HER SO	MARPAT 142:24032																

GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated (hetero)cycloalkyl; R6-R9 = H, alkyl, (un)saturated (hetero)cycloalkyl, etc.; A = CHR18, CHR18CH2; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.]

with

neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. Thus, reacting 6-chloro-1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride with 2-(2-chloroacetamide)-2',5-dichlorobenzophenone in the presence of K2CO3 in DMF followed by treating of the free base with HCl/EtOH afforded 61% III.HCl. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).

IT 844831-94-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT6 receptor affinity)

RN 844831-94-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-(CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:136549 CAPLUS

DOCUMENT NUMBER: 142:240310

TITLE: Preparation of indol-5-vl sulfonamide derivatives and

their use as 5-HT6 modulators

INVENTOR(S): Merce Vidal, Ramon; Codony Soler, Xavier; Dordal

Zueras, Alberto

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
20040729
     WO 2005013977
                                 20050217
                                           WO 2004-EP8511
                          Α1
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     ES 2222827
                          Α1
                                 20050201
                                             ES 2003-1805
                                                                     20030730
     ES 2222827
                          B1
                                 20060301
     AU 2004262485
                                 20050217
                                             AU 2004-262485
                                                                     20040729
                          Α1
     CA 2533976
                                             CA 2004-2533976
                                 20050217
                                                                     20040729
                          Α1
     EP 1648445
                                             EP 2004-763610
                                 20060426
                          Α1
                                                                     20040729
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1832740
                                20060913
                                             CN 2004-80022472
                                                                     20040729
                          Α
     BR 2004013110
                          Α
                                 20061003
                                             BR 2004-13110
                                                                     20040729
     JP 2007500165
                          Τ
                                 20070111
                                             JP 2006-521529
                                                                     20040729
     MX 2006PA01159
                          Α
                                 20060424
                                             MX 2006-PA1159
                                                                     20060127
     NO 2006000865
                                 20060222
                                             NO 2006-865
                          Α
                                                                     20060222
                                 20070208
                                             US 2006-566094
     US 20070032520
                          Α1
                                                                     20061003
                                             ES 2003-1805
PRIORITY APPLN. INFO.:
                                                                 Α
                                                                    20030730
                                             WO 2004-EP8511
                                                                 W
                                                                    20040729
OTHER SOURCE(S):
                        CASREACT 142:240310; MARPAT 142:240310
```

GΙ

AB Title compds. I [R1 = NR8R9 radical or (un)saturated-(un)substituted cycloaliph. radical optionally containing at least one heteroatom; R2-4,6-7 independently = H, NO2, alkoxy, CN, etc.; R5 = H or (un)saturated alkyl optionally at least monosubstituted; R8 or R9 independently = H or (un)saturated alkyl optionally at least monosubstituted with provisions; or R8 and R9 together with the bridging N atom form a (un)saturated-(un)substituted heterocyclic ring; A = (un)substituted mono or polycyclic aromatic ring; n = 0-4] and their pharmaceutically acceptable salts are prepared and disclosed

ΙI

as 5-HT6 modulators. Thus, e.g., II, was prepared via reaction of naphthalene-2-sulfonyl chloride with 5-amino-1-(2-dimethylaminoethyl)-1H-indole. Selected data from <math>5-HT6 receptor binding studies revealed Ki values (nM) ranging from 1.89-112.4.

IT 844831-94-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indol-5-ylsulfonamide derivs. as 5-HT6 receptor modulators)

RN 844831-94-3 CAPLUS

CN Benzenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-2-nitro-(CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 21.15 202.18 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL. SESSION ENTRY CA SUBSCRIBER PRICE -2.40-2.40

FILE 'STNGUIDE' ENTERED AT 18:11:10 ON 21 MAY 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 16, 2008 (20080516/UP).

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.36 202.54 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -2.40

STN INTERNATIONAL LOGOFF AT 18:14:40 ON 21 MAY 2008